Predigen Working to Differentiate Bacterial from Viral Infections

Jan 16, 2019 | Leo O’Connor
[Originally posted on 360dx.com]

NEW YORK (GenomeWeb) – Duke University spinout Predigen Diagnostics is developing a multiplex platform that uses host gene expression signatures as a basis for the prognostic, diagnostic, and therapeutic monitoring systems it is developing.

If all goes well, it expects to have a first product in regulatory review by the US Food and Drug Administration sometime in 2022.

One of its first products will likely be a test that helps clinicians do a better job of differentiating bacterial from viral infections, which could help mitigate some antimicrobial resistance concerns, Ephraim Tsalik, a cofounder of Predigen and associate professor of medicine at Duke, said in an interview.

Read the full story here